Evidence map›Paper›PMID 21755003›Full record

ArticlePloS one2011

Performance of risk-based criteria for targeting acute HIV screening in San Francisco.

Shelley N Facente, Christopher D Pilcher, Wendy E Hartogensis, Jeffrey D Klausner, Susan S Philip, Brian Louie, Katerina A Christopoulos, Teri Dowling, Grant N Colfax

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Using Clinical Notes and Natural Language Processing for Automated HIV Risk Assessment.Journal of acquired immune deficiency syndromes (1999) · 2018
    Article
  7. False-positive HIV nucleic acid amplification testing during CAR T-cell therapy.Diagnostic microbiology and infectious disease · 2017
    Article
  8. Real-world performance of the new US HIV testing algorithm in medical settings.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2017
    Article
  9. Article
  10. Costs per Diagnosis of Acute HIV Infection in Community-based Screening Strategies: A Comparative Analysis of Four Screening Algorithms.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Article
  11. Ten Years of Screening and Testing for Acute HIV Infection in North Carolina.Journal of acquired immune deficiency syndromes (1999) · 2016
    Article
  12. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Article
  13. Article
  14. How can we better identify early HIV infections?Current opinion in HIV and AIDS · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shelley N FacenteFacente Consulting, San Francisco, California, United States of America. shelley@facenteconsulting.com
Christopher D Pilcher
Wendy E Hartogensis
Jeffrey D Klausner
Susan S Philip
Brian Louie
Katerina A Christopoulos
Teri Dowling
Grant N Colfax
San Francisco Department of Public Health · USSan Francisco General Hospital · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Optimizing Rapid and Full Engagement in Care for Persons with Newly Diagnosed HIVK23MH092220 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTOPOULOS, KATERINA A · 2010 to 2013
$635k
NIAID NIH HHS P30 AI027763NIMH NIH HHS K23 MH092220
6 · The paper itself

Abstract

backgroundFederal guidelines now recommend supplemental HIV RNA testing for persons at high risk for acute HIV infection. However, many rapid HIV testing sites do not include HIV RNA or p24 antigen testing due to concerns about cost, the need for results follow-up, and the impact of expanded venipuncture on clinic flow. We developed criteria to identify patients in a municipal STD clinic in San Francisco who are asymptomatic but may still be likely to have acute infection.

methodsData were from patients tested with serial HIV antibody and HIV RNA tests to identify acute HIV infection. BED-CEIA results were used to classify non-acute cases as recent or longstanding. Demographics and self-reported risk behaviors were collected at time of testing. Multivariate models were developed and preliminarily evaluated using predictors associated with recent infection in bivariate analyses as a proxy for acute HIV infection. Multivariate models demonstrating ≥70% sensitivity for recent infection while testing ≤60% of patients in this development dataset were then validated by determining their performance in identifying acute infections.

resultsFrom 2004-2007, 137 of 12,622 testers had recent and 36 had acute infections. A model limiting acute HIV screening to MSM plus any one of a series of other predictors resulted in a sensitivity of 83.3% and only 47.6% of patients requiring testing. A single-factor model testing only patients reporting any receptive anal intercourse resulted in 88.9% sensitivity with only 55.2% of patients requiring testing.

conclusionsIn similar high risk HIV testing sites, acute screening using "supplemental" HIV p24 antigen or RNA tests can be rationally targeted to testers who report particular HIV risk behaviors. By improving the efficiency of acute HIV testing, such criteria could facilitate expanded acute case identification.

Indexed as

Mass ScreeningAcute DiseaseAdultCD4 Lymphocyte CountFemaleHIVHIV AntibodiesHIV InfectionsHumansMaleMiddle AgedModels, BiologicalMultivariate AnalysisPrevalenceReproducibility of ResultsRisk FactorsHIV Antibodies

Identifiers

PMID21755003
PMCPMC3130783
OpenAlexW2016358676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.